Pioneering genetic-testing company Myriad’s biggest new product is facing pushback from US regulators that could ‘significantly limit’ the test’s appeal. The stock is down 40%. (MYGN)

Pioneering genetic-testing company Myriad Genetics sells a test called GeneSight that claims to analyze a patient’s DNA and point them to the best depression drug for them. Scientists and doctors have raised concerns about GeneSight and other similar tests. Now, the FDA is asking for changes to GeneSight, Myriad Genetics disclosed on Tuesday.  Those changes “could significantly limit” broad adoption of GeneSight because it would not be able to make specific drug recommendations, JPMorgan

Continue reading...